EU panel recommends authorization of GSK diabetes drug

|By:, SA News Editor

A European Medicines Agency committee has recommended that the EU approve GlaxoSmithKline's (GSK) once-weekly Albiglutide drug for Type 2 diabetes.

The treatment belongs to the same class of GLP-1 therapies as Novo Nordisk's (NVO) Victoza, and Byetta and Bydureon from Bristol-Myers Squibb and AstraZeneca (AZN).

The European Commission usually follows the recommendations of the EMA. GSK expects a decision in Q1. (PR)